How has Ligand Pharmaceuticals's payments of debt issuance costs changed year-over-year?

Ligand Pharmaceuticals's payments of debt issuance costs decreased by 29.6% year-over-year, from $71K to $50K.

Ligand Pharmaceuticals LGND Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

RevvityRVTY

——

RepligenRGEN

——

AlkermesALKS

——

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.6B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's payments of debt issuance costs?: Ligand Pharmaceuticals (LGND) reported payments of debt issuance costs of $50K in Q1 2026.
How has Ligand Pharmaceuticals's payments of debt issuance costs changed year-over-year?: Ligand Pharmaceuticals's payments of debt issuance costs decreased by 29.6% year-over-year, from $71K to $50K.